OTCPicks.com

WGL ENTERTAINMENT HOLDINGS INCORPORATED (OTC: WEHI)
"Up 100.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/WEHI.php

WGL Entertainment Holdings, Inc., through its subsidiary WGL Entertainment, is the producer of the WGL Million Dollar Shootout Reality Television Series and several other made-for-TV sports entertainment events scheduled to be produced in 2008 and beyond.

WEHI News:

August 28 - WGL Entertainment Holdings, Inc. Agrees to Dividend Deal

WGL Entertainment Holdings, Inc. (OTC: WEHI) announced that it has agreed in principal to distribute 15,000,000 shares of a publicly traded media company to its shareholders. The shares represent approximately $100,000 at its current value. The media company whom we will identify upon closing will air the WGL Million Dollar Shootout (MDSO) reality television series through its International outlets and represent the MDSO in the U.S. market for a national network airing. At closing, which is expected by the end of next week, a record date will be set for the distribution of the shares.

"This new partnership will bring many synergies to both companies not only in the media environment, but in the pursuit of further mergers and acquisitions. The dividend being paid represents 13.3% of WGL Entertainment Holdings, Inc.'s current market capitalization," said Mike Pagnano, CEO, WGL Entertainment Holdings, Inc. "We continue to work very hard to bring value to our shareholders and appreciation of our PPS. This significant agreement is a Win-Win for all involved."

EMPIRE FILM GROUP INCORPORATED (OTC: EFGU)
"Up 83.67% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/EFGU.php

Empire Film Group, Inc. engages in the finance, production, and distribution of films. It films in various locations worldwide that include Los Angeles, Vancouver, Calgary, Toronto, France, Spain, Romania, Czech Republic, Israel, Costa Rica, Venezuela, Puerto Rico, Colombia, Cuba, Dominican Republic, Mexico, and various locations throughout the United States. The company would also co-produce and co-finance with other producers and production companies. It was formerly known as Environmental Construction Products International, Inc. and changed its name to Empire Film Group, Inc. in November 2007. The company is based in Beverly Hills, California.

EFGU News:

August 28 - Empire Posts Q2 Profit, Looks For Record Earnings in Q3

Despite a limited release slate during the second quarter of 2008, Empire Film Group, Inc. (OTC: EFGU) (www.empirefilmgroup.com) delivered a modest profit for the period ending June 30, 2008, marking the second consecutive profitable quarter for the recently formed independent studio. The company posted profits of $71,384 on revenues of $757,609, which exceeded previously released management projections for the quarter by more than 65%. For the current Q3 reporting period, Empire is projecting revenues of more than $5-million from the September 19th theatrical launch of "Hounddog," the new release non-fiction book "Made in the USA" and the DVD release of the Sidney Poitier feature "The Last Brickmaker In America."

"We're pleased to have beaten our forecasts and delivered another profitable quarter," said Dean Hamilton-Bornstein, CEO. "We had planned on the second quarter as a build-up period for the launch of major releases in the second half of the year. But new media opportunities and ongoing sales from our DVD catalog were underestimated, which is always welcomed news."

One of the new media agreements for Empire is a 20-title pay-per-view and video-on-demand agreement with Gravitas Ventures, LLC which will facilitate the digital streaming of Empire titles through major cable and satellite outlets including Time-Warner Cable, Comcast, Direct TV and Cox Communications. Another agreement was initiated with Vancouver-based Industry-Works covering the co-financing and distribution of three original productions from Empire.

"The positive momentum for Empire is building more quickly than originally anticipated," said Eric Parkinson, CEO of Empire distribution divisions Empire Home Entertainment and Hannover House. "Generally speaking, start up entertainment companies take many quarters or years to show results and even longer to show profits. Our business model and philosophy have enabled us to make prudent and profitable acquisition and releasing decisions right from the start. Producers and industry professionals are acknowledging our results and this is accelerating the volume and quality of new opportunities being presented to Empire."

Empire Film Group will be featured in a full page ad appearing in the Hollywood Reporter, August 29, as well as in Variety on September 8, collectively reaching nearly 250,000 industry professionals, producers, distributors and broadcasters worldwide.

SOUTHRIDGE ENTERPRISES INCORPORATED (OTCBB: SRDG)
"Up 66.67% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/SRDG.php

Southridge Enterprises is a renewable energy company with a mission to become the ethanol producer of choice. The Company is focusing its efforts in an area which offers abundant supplies of corn, superior transportation infrastructure and expedited permitting processes. The Company is actively acquiring and developing ethanol production facilities and anticipates start-up of the first phase of these operations in 2009. Southridge Enterprises is headquartered in Dallas, Texas.

SRDG News:

August 25 - Southridge Receives $7.5 Million for Brazil Ethanol Plant

Southridge Enterprises, Inc. (OTCBB: SRDG) (the "Company") announced that the Company's subsidiary, Southridge Brasilia Corp. ("SBC"), has received a total of $7,500,000 from its project partners for the construction of the ethanol facility in Brazil.

Southridge director, Mr. Marcio Santos, has been working closely with our Brazilian partners Durmundo Carasca SA (DCSA) and Briskul Transaccao LTDA (BTL) in the development of the Company's plant in Brazil. DCSA has now completed their $5,000,000 contribution for their 15% interest in the new facility. In addition, BTL has exercised their option to increase their position in SBC for an additional $3,270,000, bringing their total interest to 35%.

The ethanol industry in the United States is facing diminishing profit margins that have put many viable and well-funded projects in an increasingly difficult position to continue operations. Due to the high commodity prices for corn and natural gas in United States, Southridge management has decided to put both the Mississippi and Texas ethanol plants on hold until market conditions improve the viability of these projects. As a result, the Company has refocused and accelerated the development of the El Salvador and Brazil plants, as well as increased the revenue from our ethanol sales efforts.

Dallas-based Southridge is developing ethanol plants in El Salvador and Brazil.

DEMATCO INCORPORATED (OTCBB: DMAT)
"Up 33.33% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/DMAT.php

DeMatco, Inc. provides proprietary dematerialization services to the securities industry primarily in the United Kingdom. It converts financial instruments from paper form to electronic form so as to enable such instruments to be traded electronically on exchanges or exchange platforms on a peer to peer basis. The company was founded in 2005 and is based in Encino, California.

DMAT News:

August 26 - Dematco, Inc. Announces Another European Investor Group to Dematerialize More Senior Life Settlement Policies Through Dematco, Ltd.

Dematco, Inc. (OTCBB: DMAT) announced that its wholly-owned subsidiary Dematco, Ltd. has been engaged by another leading European investor group to dematerialize more Senior Life Settlement Units (SLSU) from Senior Life Settlement policies. Dematco, Ltd. converts all manner of paper instruments into electronically transferable units; and for this their second contract the Company received an initial stage payment of $75,000. A $30,000,000 face value project, Dematco expects to receive $525,000 in payment for services upon completion of the dematerialization. The units will be traded through Private Trading Systems PLC (PlusMarkets:PTSP), a proprietary trading and clearing system. The Company has a working business relationship with Private Trading Systems.

Robert Stevens, Chairman of Dematco, Inc. comments, "Signing our second contract in just two weeks, we appear to be well positioned in this underserved market. Our dematerialization process seems to be the product the investor groups want. We expect to announce more agreements that significantly grow our client base impacting our expanding revenues.”

CYBERLUX CORPORATION (OTCBB: CYBL)
"Up 27.69% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/CYBL.php

Cyberlux Corporation, a leader in solid-state lighting innovation, has developed breakthrough LED lighting technology that provides the most energy efficient and cost effective portable lighting solutions available today for military and commercial uses. The Military and Homeland Security products provide tactical covert and visible lighting capability and are designed as highly mobile, battery-powered lighting systems ideal for threat detection, force and asset protection and general expeditionary lighting needs.

CYBL News:

August 28 - Cyberlux Corporation Awarded Additional U.S. Patent Claims for BrightEye / WatchDog Portable Light Devices

The U.S. Patent Office grants 21 additional patent claims in Portable Light Device U.S. Patent Application

Cyberlux Corporation (OTCBB: CYBL), a leading provider of LED lighting solutions, announced that the U.S. Patent Office has recently awarded patent protection for 21 claims contained within the Company's U.S. Patent Application for Portable Light Device, Application Number 11/336,562 filed on January 21, 2006. The new patent claims define specific areas of patent protection for the Company's BrightEye and WatchDog portable lighting products and augment the 29 patent claims announced in May 2008. In combination, the 50 patent claims provide Cyberlux with thorough patent protection for its WatchDog and BrightEye family of tactical lighting products, as well as any future products developed on this patent foundation.

"Cyberlux continues to be a leader in solid-state LED lighting innovation, and these additional 21 patent claims will extend the scope of patent protection we have on our breakthrough tactical lighting systems. In addition, this patent foundation will provide the technical basis for future product development and new product engineering advances," said Mark Schmidt, president and chief executive officer for Cyberlux. "With the Company's continued focus on profitability and growth, the development of innovative, patentable solid-state LED lighting technology is a strategic imperative and a keystone component of our long-term growth."

The new claims awarded by the U.S. Patent Office address a lighting device comprised of an array of LEDs that operate in spot-light and flood-light modes of illumination, or in a spot-light/flood-light combined mode, with alterable intensity levels, controlled by an electrical power system and electrical sensor operation. Further, the new claims cover the user interface that allows the user to change operating modes continuously between spot-light and flood- light illumination and to display the battery power capacity on a percentage and time interval basis.

In addition, the claims address the specifics around the use of narrowing lenses as LED optics adapted to focus illumination in a cone angle between 4 and 50 degrees. This unique optical method and practice enable the spot-light and flood-light modes of illumination.

Lastly, the claims address the use of a computer and computer-executable programming instructions for operating a lighting device. The operations are defined as comprising the steps of sensing electrical power information, sensing modes of illumination information and sensing LED intensity information provided by a user via the user interface, directing the array of LEDs to operate in either a spot-light, flood-light or combined mode of illumination, directing the array of LEDs to operate at a desired intensity level, and displaying the power supply capacity message to the user based upon the sensed electrical power, mode of illumination and LED intensity information.

These newly awarded 21 patent claims provide Cyberlux with a deeper, more extensible intellectual property platform for the current tactical lighting system products and for future lighting systems currently under development. Importantly, the combined 50 patent claims create a significant licensing portfolio that will allow other companies access to these fundamental LED lighting capabilities.

CELL GENESYS INCORPORATED (NASDAQ: CEGE)
"Up 29.92% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/CEGE.php

Cell Genesys, Inc., a biotechnology company, engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies. The company's GVAX cancer Immunotherapies comprise Prostate Cancer, a phase III product for the treatment of prostate cancer; Pancreatic Cancer, a phase II product for pancreatic cancer; and Leukemia, a phase II product for the treatment of acute and chronic myelogenous leukemia, and myelodysplastic syndrome. Its Oncolytic Virus Therapy includes CG0070, a phase I product for the treatment of recurrent bladder cancer. Cell Genesys has alliance with Novartis AG for the development and commercialization of oncolytic virus therapies; research and development collaboration with Medarex, Inc.; and development and commercialization collaboration of GVAX immunotherapy with Takeda Pharmaceutical Company Limited for prostate cancer. The company was founded in 1988 and is headquartered in South San Francisco, California.

CEGE News:

August 27 - Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere® (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer. The Company ended the trial as recommended by its Independent Data Monitoring Committee (IDMC) which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study.

To date, VITAL-2 enrolled 408 patients. The IDMC based its recommendation on 114 deaths of which 67 occurred in the GVAX plus Taxotere combination treatment arm and 47 deaths occurred in the Taxotere control arm. At this time, a specific cause for the imbalance in deaths has not been identified and the IDMC reported no new safety issues for GVAX when administered in combination with Taxotere. The Company plans to fully analyze the clinical data from these patients to attempt to understand the potential cause for the higher rate of deaths observed in the GVAX immunotherapy plus Taxotere combination arm, including an assessment of potential imbalances between the two arms of the study such as baseline characteristics and prognostic factors, as well as other treatment variables. In light of the IDMC’s observation with respect to VITAL-2, the Company has requested that the IDMC perform a previously unspecified futility analysis of VITAL-1, the other Phase 3 clinical trial of GVAX immunotherapy for prostate cancer. The Company expects the results of the VITAL-1 futility analysis in approximately one month.

"Patient safety is always our paramount concern and so we have immediately responded to the recommendation of the IDMC. We are currently notifying all participating clinical trial sites and regulatory agencies that enrollment of new patients into VITAL-2 has been suspended as has treatment with GVAX immunotherapy for prostate cancer of patients enrolled in the study," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. “Notwithstanding this disappointing outcome, we would like to acknowledge the courage and commitment of the patients and physicians who have participated in this trial.”

Dr. Sherwin continued, “The observation in the VITAL-2 trial is very surprising to us, and we have therefore asked the IDMC to conduct a previously unplanned futility analysis of VITAL-1 in order to determine the overall prospects for our ongoing development program for this product. Moreover, with the cessation of VITAL-2, we expect to make commensurate adjustments to our business operations and we will provide further details regarding this in the near future. As a reminder, the company ended the second quarter of 2008 with $166 million in cash."

VITAL-2 was a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in hormone-refractory prostate cancer (HRPC) patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial was an improvement in survival. VITAL-2 was initiated in June 2005 and to date had enrolled 408 patients at 115 clinical trial sites located in North America and the European Union. VITAL-1, the other Phase 3 clinical trial of GVAX immunotherapy for prostate cancer, is designed to compare GVAX cancer immunotherapy as a monotherapy to Taxotere chemotherapy plus prednisone in earlier stage HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. In 2007, the VITAL-1 trial completed enrollment with 626 patients. In January 2008, Cell Genesys announced that the IDMC had completed a pre-planned interim analysis for VITAL-1 and recommended that the study continue, providing no further information to the company other than the recommendation to continue the trial.

ABOUT GVAX IMMUNOTHERAPY FOR PROSTATE CANCER

GVAX immunotherapy for prostate cancer is comprised of two prostate tumor cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine that plays a key role in stimulating the body's immune response, and then irradiated for safety. GVAX immunotherapy for prostate cancer is designed to be administered through intradermal injections on an outpatient basis.